Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20815357 | 1.00 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 | |
| SCHEMBL15528350 | 0.92 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 | |
| SCHEMBL5021113 | 0.73 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 | |
| SCHEMBL27912633 | 0.70 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 | |
| SCHEMBL17282999 | 0.67 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 | |
| SCHEMBL31555007 | 0.67 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 | |
| SCHEMBL16411604 | 0.67 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 | |
| SCHEMBL15609349 | 0.67 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2NOS1MAPTKDM4E | |
| SCHEMBL4561284 | 0.64 | — | — | |
| SCHEMBL15528437 | 0.64 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NOS1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844658-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-9212186-B2 | Bicyclic pyrazole LRRK2 small molecule inhibitors | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2844658-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2013164323-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | LRRK2, PARK7, PINK1 | ALDH1A1 2479/4885SMN1; SMN2 1120/4885NOS1 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.